QQQ   444.47 (-0.08%)
AAPL   170.92 (-1.38%)
MSFT   420.85 (-0.14%)
META   488.12 (-1.16%)
GOOGL   150.51 (-0.24%)
AMZN   180.76 (+0.52%)
TSLA   176.29 (-1.97%)
NVDA   905.25 (+0.30%)
NIO   4.61 (-1.28%)
AMD   181.46 (+1.04%)
BABA   72.51 (+1.29%)
T   17.57 (+0.11%)
F   13.28 (+1.68%)
MU   118.47 (-0.56%)
CGC   9.45 (-1.05%)
GE   175.44 (-2.60%)
DIS   122.70 (+1.42%)
AMC   3.69 (-14.98%)
PFE   27.88 (+0.36%)
PYPL   66.82 (+0.38%)
XOM   115.52 (+0.48%)
QQQ   444.47 (-0.08%)
AAPL   170.92 (-1.38%)
MSFT   420.85 (-0.14%)
META   488.12 (-1.16%)
GOOGL   150.51 (-0.24%)
AMZN   180.76 (+0.52%)
TSLA   176.29 (-1.97%)
NVDA   905.25 (+0.30%)
NIO   4.61 (-1.28%)
AMD   181.46 (+1.04%)
BABA   72.51 (+1.29%)
T   17.57 (+0.11%)
F   13.28 (+1.68%)
MU   118.47 (-0.56%)
CGC   9.45 (-1.05%)
GE   175.44 (-2.60%)
DIS   122.70 (+1.42%)
AMC   3.69 (-14.98%)
PFE   27.88 (+0.36%)
PYPL   66.82 (+0.38%)
XOM   115.52 (+0.48%)
QQQ   444.47 (-0.08%)
AAPL   170.92 (-1.38%)
MSFT   420.85 (-0.14%)
META   488.12 (-1.16%)
GOOGL   150.51 (-0.24%)
AMZN   180.76 (+0.52%)
TSLA   176.29 (-1.97%)
NVDA   905.25 (+0.30%)
NIO   4.61 (-1.28%)
AMD   181.46 (+1.04%)
BABA   72.51 (+1.29%)
T   17.57 (+0.11%)
F   13.28 (+1.68%)
MU   118.47 (-0.56%)
CGC   9.45 (-1.05%)
GE   175.44 (-2.60%)
DIS   122.70 (+1.42%)
AMC   3.69 (-14.98%)
PFE   27.88 (+0.36%)
PYPL   66.82 (+0.38%)
XOM   115.52 (+0.48%)
QQQ   444.47 (-0.08%)
AAPL   170.92 (-1.38%)
MSFT   420.85 (-0.14%)
META   488.12 (-1.16%)
GOOGL   150.51 (-0.24%)
AMZN   180.76 (+0.52%)
TSLA   176.29 (-1.97%)
NVDA   905.25 (+0.30%)
NIO   4.61 (-1.28%)
AMD   181.46 (+1.04%)
BABA   72.51 (+1.29%)
T   17.57 (+0.11%)
F   13.28 (+1.68%)
MU   118.47 (-0.56%)
CGC   9.45 (-1.05%)
GE   175.44 (-2.60%)
DIS   122.70 (+1.42%)
AMC   3.69 (-14.98%)
PFE   27.88 (+0.36%)
PYPL   66.82 (+0.38%)
XOM   115.52 (+0.48%)
NASDAQ:OCUL

Ocular Therapeutix (OCUL) Stock Price, News & Analysis

$9.47
+0.16 (+1.72%)
(As of 11:40 AM ET)
Today's Range
$9.09
$9.50
50-Day Range
$3.85
$10.93
52-Week Range
$2.00
$11.31
Volume
280,558 shs
Average Volume
2.06 million shs
Market Capitalization
$1.41 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.80

Ocular Therapeutix MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
82.2% Upside
$16.80 Price Target
Short Interest
Bearish
6.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.01
Upright™ Environmental Score
News Sentiment
0.82mentions of Ocular Therapeutix in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$7 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.01 out of 5 stars

Medical Sector

214th out of 939 stocks

Pharmaceutical Preparations Industry

91st out of 433 stocks

OCUL stock logo

About Ocular Therapeutix Stock (NASDAQ:OCUL)

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

OCUL Stock Price History

OCUL Stock News Headlines

Ocular Therapeutix (NASDAQ:OCUL) Stock Price Down 5.8%
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Q4 2023 Clearside Biomedical Inc Earnings Call
Ocular Therapeutix (NASDAQ:OCUL) Upgraded at StockNews.com
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
OCUL Apr 2024 12.500 put
Decoding 6 Analyst Evaluations For Ocular Therapeutix
Ocular Therapeutix: Q4 Earnings Snapshot
Ocular Therapeutix earnings: here's what Wall Street expects
Earnings Outlook For Ocular Therapeutix
See More Headlines
Receive OCUL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OCUL
Employees
267
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.80
High Stock Price Target
$24.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+83.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-80,740,000.00
Net Margins
-138.15%
Pretax Margin
-138.15%

Debt

Sales & Book Value

Annual Sales
$58.44 million
Book Value
$0.79 per share

Miscellaneous

Free Float
140,453,000
Market Cap
$1.36 billion
Optionable
Optionable
Beta
1.32
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Antony MattessichMr. Antony Mattessich (Age 56)
    President, CEO & Director
    Comp: $1.05M
  • Mr. Donald Notman Jr.
    Chief Financial Officer
  • Dr. Jeffrey S. Heier M.D. (Age 63)
    Chief Scientific Officer
    Comp: $84.88k
  • Dr. Rabia Gurses Ozden M.D. (Age 56)
    Chief Medical Officer
    Comp: $621.39k
  • Dr. Pravin U. Dugel M.D. (Age 60)
    Executive Chairman
  • Dr. Peter K. Jarrett Ph.D. (Age 67)
    Chief Technology Officer
  • Mr. Philip C. Strassburger Esq. (Age 64)
    General Counsel
    Comp: $282.61k
  • Mr. William H. Ransone II
    Vice President of Global Sales & Marketing
  • Ms. Tracy Smith
    Vice President of Human Resources
  • Mr. Christopher G. White (Age 62)
    Chief Business Officer

OCUL Stock Analysis - Frequently Asked Questions

Should I buy or sell Ocular Therapeutix stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OCUL shares.
View OCUL analyst ratings
or view top-rated stocks.

What is Ocular Therapeutix's stock price target for 2024?

5 brokerages have issued 12 month price objectives for Ocular Therapeutix's shares. Their OCUL share price targets range from $12.00 to $24.00. On average, they predict the company's share price to reach $16.80 in the next twelve months. This suggests a possible upside of 82.2% from the stock's current price.
View analysts price targets for OCUL
or view top-rated stocks among Wall Street analysts.

How have OCUL shares performed in 2024?

Ocular Therapeutix's stock was trading at $4.46 at the start of the year. Since then, OCUL stock has increased by 106.7% and is now trading at $9.22.
View the best growth stocks for 2024 here
.

When is Ocular Therapeutix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our OCUL earnings forecast
.

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) issued its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.03. The biopharmaceutical company had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.13 million. Ocular Therapeutix had a negative net margin of 138.15% and a negative trailing twelve-month return on equity of 321.12%. During the same period last year, the firm earned ($0.17) EPS.

What ETFs hold Ocular Therapeutix's stock?

ETFs with the largest weight of Ocular Therapeutix (NASDAQ:OCUL) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

Who are Ocular Therapeutix's major shareholders?

Ocular Therapeutix's stock is owned by many different retail and institutional investors. Top institutional shareholders include Opaleye Management Inc. (7.64%), Vanguard Group Inc. (6.44%), Vanguard Group Inc. (6.44%), Franklin Resources Inc. (5.67%), Deltec Asset Management LLC (3.08%) and Nuveen Asset Management LLC (1.27%). Insiders that own company stock include Antony C Mattessich, Christopher G White, Donald Notman, Philip C Strassburger, Rabia Gurses Ozden, Richard L Md Lindstrom and Summer Road Llc.
View institutional ownership trends
.

How do I buy shares of Ocular Therapeutix?

Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OCUL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners